Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line pembrolizumab in elderly patients with PD-L1-positive advanced NSCLC
2016-004353-32Phase 2Active
- Sponsor
- Fundación GECP
- Start
- Jul 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Fundación GECP. Primary endpoint: Overall survival at one year. Started Jul 2017; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-004353-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004353-32.